Promising drug cocktail aims to eradicate hidden breast cancer cells
NCT ID NCT04434040
First seen May 06, 2026 · Last updated Jun 16, 2026 · Updated 9 times
Summary
This study tests whether combining two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes of people with triple negative breast cancer. About 40 participants who still have cancer after standard chemotherapy will receive the combination. The main goal is to see if the drugs can make cancer DNA disappear from the blood, which may lower the risk of the cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94115, United States
Contact Email: •••••@•••••
Contact
-
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
WITHDRAWNNew Lenox, Illinois, 60451, United States
-
University of Chicago Medical Center
WITHDRAWNChicago, Illinois, 60637, United States
-
University of Chicago Medical Center for Advanced Care Orland Park
WITHDRAWNOrland Park, Illinois, 60462, United States
-
University of Pennsylvania-Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.